Options360

Enzo Biochem spiked on 43x average volume

Options360 Updated   
NYSE:ENZ   Enzo Biochem, Inc.
Enzo Biochem spiked on 43x average volume. This is highly volatile price action. Enzo Biochem (ENZ) reported Quarter January 2021 earnings of $0.09 per share on revenue of $31.5 million. Revenue grew 62.3% on a year-over-year basis. Enzo Biochem Inc is engaged in research, development, manufacturing and marketing of health care products, platforms and services. The Company provides clinical laboratory services. ENZ proprietary system for detection of the coronavirus SARS-CoV-2 is GENFLEX.

breakout = $4.56
R3 = $4.36
R2 = $4.16
R1 = $3.99
pivot = $3.73
S1 = $3.60
S2 = $3.41
S3 = $3.22
break down = $3.04

Do your own due diligence, your risk is 100% your responsibility. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Small incremental steps work : If you double a penny a day for a month it = $5,368,709. Good luck and happy trading friends...

*3x lucky 7s of trading*

7pt Trading compass:
Price action, entry/exit
Volume average/direction
Trend, patterns, momentum
Newsworthy current events
Revenue
Earnings
Balance sheet

7 Common mistakes:
+5% portfolio trades, risk management
Beware of analysts motives
Emotions & Opinions
FOMO : bad timing
Lack of planning & discipline
Forgetting restraint
Obdurate repetitive errors, no adaptation

7 Important tools:
Trading View app!, Brokerage UI
Accurate indicators & settings
Wide screen monitor/s
Trading log (pencil & graph paper)
Big organized desk
Reading books, playing chess
Sorted watch-list

Checkout my indicators:
Fibonacci VIP - volume
Fibonacci MA7 - price
pi RSI - trend momentum
TTC - trend channel
AlertiT - notification
www.tradingview.com/u/growerik/
Trade active:
ENZ straddle
4/16 expiry
$2.5 call & put

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.